Pfizer acquires CureVac

BioNTech has completed the acquisition of CureVac for $1.25 billion, effectively concluding the latter's run as a publicly traded entity. The acquisition results in the cessation of trading for CureVac shares on Nasdaq, with a formal delisting expected by mid-January. This move integrates CureVac's assets, including its Tübingen manufacturing facility and oncology pipeline, into BioNTech's operations, ending its independent market presence after a tumultuous period marked by fluctuating stock performance.

Under the terms of the deal, CureVac shareholders will receive BioNTech American Depositary Shares valued at approximately $5.46 per share, which reflects a 55% premium over CureVac's three-month average trading price of $3.53 preceding the offer. Prior to the acquisition’s finalization, CureVac's stock was trading at $4.66. The tender offer, completed on December 18, 2025, allowed BioNTech to acquire 195,341,219 CureVac shares, representing about 86.75% of the company's equity. Subsequent compulsory acquisition of the remaining shares occurred in early January 2026.

This strategic procurement is pivotal for BioNTech's aim to strengthen its oncology capabilities, especially with plans to harness CureVac's Tübingen site for personalized cancer vaccine production. Additionally, the acquisition resolves longstanding legal entanglements; BioNTech previously settled patent infringement claims linked to its COVID-19 vaccine, Comirnaty, through an $870 million settlement, allotting $370 million to CureVac. This agreement not only mitigates a significant legal risk but also paves the way for BioNTech’s expansion efforts unhindered by patent disputes.

The acquisition occurs within a broader context of litigation in the mRNA technology space. Shortly after closing the deal, Bayer initiated a lawsuit against BioNTech, Pfizer, and Moderna concerning patents from the Monsanto portfolio related to mRNA stabilization—a matter now implicated in BioNTech’s new legal responsibilities following CureVac’s integration.

Going forward, CureVac is set to formally submit necessary filings to terminate its SEC registration, with deregistration anticipated within 90 days post-filing. Market reactions have been lukewarm, reflecting concerns over share dilution and the financial weight of prior legal settlements. As BioNTech proceeds with CureVac's incorporation, the biotech sector remains attentive to evolving patent disputes and regulatory processes that could affect market positions and competitive strategies.